Dermatology · Alopecia AreataTrial Updateclinicalmid-term

Eli Lilly's LY4005130 Trial for Severe Alopecia Areata Underway

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Eli Lilly81 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 12:31:18 AM

Assessment confidence: 89% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

Eli Lilly's ongoing trial of LY4005130 for severe alopecia areata is significant as it could introduce a new treatment option in a competitive dermatology landscape. The trial's success may enhance Eli Lilly's portfolio and market position in this therapeutic area. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 15 ranked evidence items (15 high-relevance).

Strategic Assessment

Success in this trial could enhance Eli Lilly's portfolio in dermatology and provide a new treatment option for patients with severe hair loss. The strongest clinical anchor is A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (ClinicalTrials.gov), entity match (eli lilly). In Dermatology · Alopecia Areata, 1 regulatory and 4 competitive items passed relevance filtering for Eli Lilly.

Competitive Pressure

The most relevant competitive pressure comes from FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis (Lilly) — entity match (eli lilly). FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia (FDA). Sponsor/company relevance (Lilly). The trial's outcomes will be critical for regulatory approval, influencing the drug's labeling and market entry strategy.

Key Risks

Elevated medium regulatory exposure for Eli Lilly could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, LY4005130 could capture market share from existing therapies, potentially leading to increased revenue for Eli Lilly in the dermatology sector.
Upside for Eli Lilly may improve if A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial could enhance Eli Lilly's portfolio in dermatology and provide a new treatment option for patients with severe hair loss.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes after the 48-week study period.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
ClinicalTrials.govhigh relevance
Entity match (eli lilly)
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
Lillyhigh relevance
Entity match (eli lilly)
FDA document
View source
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Lilly's retatrutide shows significant weight loss in Phase 3 obesity trials
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)
Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)

Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Peer-delivered combined EMD and imagery rescripting for traumatized Chinese university students: RCT.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
The Effect of Moxibustion at the Dazhui Point on Hypothermia and Maternal Comfort During Cesarean Delivery: A Randomized Controlled Trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Eli Lilly

Commercial impact

medium

If successful, LY4005130 could capture market share from existing therapies, potentially leading to increased revenue for Eli Lilly in the dermatology sector.

Regulatory impact

medium

The trial's outcomes will be critical for regulatory approval, influencing the drug's labeling and market entry strategy.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes after the 48-week study period.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.